Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
MENLO PARK, Calif., Feb. 10, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the RBC Capital Markets 2016 Global Healthcare Conference in New York at 8:30 a.m. Eastern Time on Tuesday, February 23.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://www.veracast.com/webcasts/rbc/healthcare2016/04102457748.cfm. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
